综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响

doi:10.3969/j.issn.1006-7795.2020.04.004

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (4): 520-524.doi: 10.3969/j.issn.1006-7795.2020.04.004

综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响

王宾红¹, 阮祥燕¹, 鞠蕊¹, 豆竹丽¹, 秦爽¹, 张露平¹, 许新¹, 杨瑜¹, Alfred O. Mueck^1,2

1. 首都医科大学附属北京妇产医院内分泌科, 北京 100026;
2. 德国图宾根大学妇产医院妇女健康部与妇女健康研究中心, 图宾根D-72076, 德国

收稿日期:2020-05-08 出版日期:2020-08-21 发布日期:2020-07-22
通讯作者: 阮祥燕 E-mail:ruanxiangyan@163.com
基金资助:
北京市医院管理中心"登峰"计划专项经费资助（DFL20181401），首都卫生发展科研专项（2020-2-2112）。

Effect of comprehensive intervention on androgen level in patients with polycystic ovary syndrome

Wang Binhong¹, Ruan Xiangyan¹, Ju Rui¹, Dou Zhuli¹, Qin Shuang¹, Zhang Luping¹, Xu Xin¹, Yang Yu¹, Alfred O. Mueck^1,2

1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. Department for Women's Health, University Women's Hospital and Research Center for Women's Health, University of Tuebingen, Tuebingen D-72076, Germany

Received:2020-05-08 Online:2020-08-21 Published:2020-07-22
Supported by:
This study was supported by Beijing Municipal Administration of Hospitals'Ascent Plan(DFL20181401),Capital's Funds for Health Improvement and Research (2020-2-2112).

摘要/Abstract

摘要： 目的评估多囊卵巢综合征（polycystic ovary syndrome，PCOS）患者经综合干预治疗后雄激素浓度的变化。方法选取2019年3月至2020年2月就诊于首都医科大学附属北京妇产医院接受综合干预治疗的PCOS患者88例为PCOS组，按2：1的比例匹配同期就诊的健康女性44例为对照组，比较PCOS组治疗前后、PCOS组治疗后与对照组观察指标间的差异，包括：体质量指数（body mass index，BMI）、腰围、卵泡刺激素（follicle stimulating hormone，FSH）、黄体生成素（luteinizing hormone，LH）、LH/FSH、总睾酮（total testosterone，TT）、游离睾酮（free testosterone，FT）、性激素结合球蛋白（sex hormone binding globulin，SHBG）、抗苗勒管激素（anti Müllerian hormone，AMH）。结果治疗前两组患者年龄、身高差异无统计学意义（P>0.05），PCOS组患者的体质量、BMI、腰围、AMH、LH、LH/FSH、TT、FT均显著高于对照组（P<0.05），FSH、SHBG显著低于对照组（P<0.05）；PCOS组综合干预治疗前后比较，体质量、BMI、腰围、AMH、TT、FT、LH、LH/FSH均显著下降（P<0.05），SHBG显著升高（P<0.05）；治疗后PCOS组与同期对照组的AMH、LH/FSH、TT比较，差异无统计学意义（P>0.05）。结论综合干预治疗3个月后能显著降低PCOS患者的雄激素浓度，尤其总睾酮浓度达到健康女性浓度。

关键词: 多囊卵巢综合征, 总睾酮, 游离睾酮, 性激素结合球蛋白

Abstract: Objective To evaluate the changes of androgen level in patients with polycystic ovary syndrome (PCOS) after comprehensive intervention. Methods A total of 88 women (PCOS group) who were willing to receive comprehensive intervention were selected as the study group from the patients with PCOS in Beijing Obstetrics and Gynecology Hospital, Capital Medical University, from March 2019 to February 2020. Totally 44 healthy women were included as the control group in the same period according to the proportion of 2:1. The observation indexes were compared with each other before and after treatment in PCOS group and between PCOS group and control group after treatment. Observation indexes include:body mass index (BMI),aist circumference、follicle stimulating hormone(FSH),luteinizing hormone(LH),LH/FSH,total testosterone(TT),free testosterone(FT),sex hormone binding globulin(SHBG),anti-Müllerian hormone(AMH). Results Before treatment, there was no significant difference in age and height between the two groups (P>0.05). The weight, BMI, waist circumference, AMH, LH, LH/FSH, and TT were significantly higher whereas FSH and SHBG were significantly lower than those of the control group (P<0.05). In PCOS group, before and after comprehensive intervention treatment, weight, BMI, waist circumference, AMH, TT, FT, LH, and LH/FSH decreased significantly (P<0.05), whereas SHBG increased significantly (P<0.05). There was no significant difference in AMH, LH/FSH, and TT between PCOS and control groups after treatment (P>0.05). Conclusion After 3 months of comprehensive intervention, the androgen level of PCOS patients was significantly decreased, especially the total testosterone level reached the level of healthy women.

Key words: polycystic ovary syndrome, total testosterone, free testosterone, sex hormone binding globulin

中图分类号:

R711

王宾红, 阮祥燕, 鞠蕊, 豆竹丽, 秦爽, 张露平, 许新, 杨瑜, Alfred O. Mueck. 综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响[J]. 首都医科大学学报, 2020, 41(4): 520-524.

Wang Binhong, Ruan Xiangyan, Ju Rui, Dou Zhuli, Qin Shuang, Zhang Luping, Xu Xin, Yang Yu, Alfred O. Mueck. Effect of comprehensive intervention on androgen level in patients with polycystic ovary syndrome[J]. Journal of Capital Medical University, 2020, 41(4): 520-524.

参考文献 19

[1]	宋颖,李蓉. 多囊卵巢综合征中国诊疗指南解读[J].实用妇产科杂志,2018,34(10):737-741.
[2]	Zeng X,Xie Y J, Liu Y T, et al. Polycystic ovarian syndrome:correlation between hyperandrogenism, insulin resistance and obesity[J]. Clin Chim Acta,2020,3(502):214-221.
[3]	Sanchez-Garrido M A,Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome:pathogenic role of androgen excess and potential therapeutic strategies[J]. Mol Metab,2020,5(35):100937.
[4]	Lizneva D,Suturina L,Walker W,et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome[J]. Elsevier Inc,2016, 106(1):6-15.
[5]	March W A,Moore V M,Willson K J,et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria[J]. Hum Reprod,2010,25(2):544-551.
[6]	张美微,侯丽辉,李妍,等.多囊卵巢综合征相关合并症的研究进展[J].现代中西医结合杂志,2020,29(2):214-219.
[7]	Pan J X,Liu Y,Ke Z H,et al. Successive and cyclic oral contraceptive pill pretreatment improves IVF/ICSI outcomes of PCOS patients and ameliorates hyperandrogenism and antral follicle excess[J]. Gynecol Endocrinol, 2015,1(4):332-336.
[8]	Li Y,Ruan X,Wang H,et al. Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment[J]. Fertil Steril, 2018,109(4):720-727.
[9]	中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J].中华妇产科杂志,2018,53(1):2-6.
[10]	Calzada M,López N,Noguera J A, et al. AMH in combination with SHBG for the diagnosis of polycystic ovary syndrome[J]. J Obstet Gynaecol, 2019,39(8):1130-1136.
[11]	Li G,Huang W,Zhang L, et al. A prospective cohort study of early-pregnancy risk factors for gestational diabetes in polycystic ovarian syndrome[J]. Diabetes Metab Res Rev, 2018,34(5):e3003.
[12]	Tian X,Ruan X,Mueck A O,et al. Serum anti-Müllerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China[J]. Gynecol Endocrinol, 2014, 30(11):836-839.
[13]	Zhao Y, Ruan X, Mueck A O. Clinical and laboratory indicators of polycystic ovary syndrome in Chinese Han nationality with different Rotterdam criteria-based phenotypes[J]. Gynecol Endocrinol, 2016,32(2):151-156.
[14]	郑荣荣,袁为标,周蓉,等.口服避孕药增加静脉血栓发病率的Meta分析[J].现代妇产科进展,2019,28(10):774-780.
[15]	战思恩,于朝.性激素结合球蛋白与多囊卵巢综合征患者肥胖、血糖、胰岛素及性激素的相关性研究[J].中国妇幼保健,2019,34(10):2229-2231.
[16]	罗卓野,张杰,郝桂敏.多囊卵巢综合征伴肥胖者助孕前处理[J].中国实用妇科与产科杂志,2019,35(3):287-291.
[17]	Cesta C E,MÅnsson M,Palm C,et al. Polycysti covary syndrome and psychiatric disorders:Comorbidity and heritability in a nation wide Swedish cohort[J]. Psychoneuroendocrinology,2016, 73(11):196-203.
[18]	杨荔凡,张艳.屈螺酮炔雌醇复合片对多囊卵巢综合征患者的有效性探讨[J].中外女性健康研究,2019,12(23):85,101.
[19]	闵敏,阮祥燕,赵越,等. 奥利司他综合干预对超重或肥胖型PCOS患者雄激素及糖脂代谢的影响[J].首都医科大学学报,2019,40(4):572-577.

综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响

Effect of comprehensive intervention on androgen level in patients with polycystic ovary syndrome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 19

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李健, 白文佩, 江波, 白栎然, 吴凤云. 生酮饮食对超重/肥胖多囊卵巢综合征女性月经及生育力的影响[J]. 首都医科大学学报, 2021, 42(6): 1021-1025.
[2]	王虎生, 阮祥燕, 程姣姣, Alfred O. Mueck. 肥胖型多囊卵巢综合征的氧化应激与脂代谢关系的研究[J]. 首都医科大学学报, 2021, 42(4): 540-546.
[3]	杨瑜, 阮祥燕, 鞠蕊, 许新, 谷牧青, 程姣姣. 屈螺酮炔雌醇Ⅱ对多囊卵巢综合征患者血清抗苗勒管激素的影响[J]. 首都医科大学学报, 2021, 42(4): 547-552.
[4]	刘真, 殷冬梅, 战思恩, 阮祥燕. 黄连素改善多囊卵巢综合征患者代谢异常的系统评价[J]. 首都医科大学学报, 2021, 42(4): 588-595.
[5]	王景尚, 尹晓丹, 何军琴, 武颖, 张莹, 李宪锐. 来曲唑联合高糖高脂饮食构建多囊卵巢综合征伴胰岛素抵抗大鼠模型研究[J]. 首都医科大学学报, 2021, 42(3): 436-442.
[6]	张黎锐, 郑薇, 刘程, 梁馨, 张莉, 田志红, 李光辉. 多囊卵巢综合征孕妇妊娠期增重模式与母儿结局的关系[J]. 首都医科大学学报, 2021, 42(2): 169-176.
[7]	闵敏, 阮祥燕, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响[J]. 首都医科大学学报, 2020, 41(4): 514-519.
[8]	豆竹丽, 阮祥燕, 鞠蕊, 王宾红, 秦爽, 许新, 杨瑜, 张露平. 综合干预后多囊卵巢综合征不孕患者应用来曲唑促排卵的临床效果[J]. 首都医科大学学报, 2020, 41(4): 525-529.
[9]	秦爽, 阮祥燕, 王宾红, 鞠蕊, 张露平, 豆竹丽, 程姣姣, 金婧. 多囊卵巢综合征患者促排卵周期中成熟卵泡性激素浓度对妊娠的影响[J]. 首都医科大学学报, 2020, 41(4): 530-535.
[10]	阮祥燕, 张露平, 代荫梅, 王虎生, 金凤羽, 谷牧青, 程姣姣, 鞠蕊, 闵敏, Thomas Roemer. 门诊微型宫腔镜检查在不孕症患者中的临床应用[J]. 首都医科大学学报, 2019, 40(4): 549-553.
[11]	谷牧青, 李扬璐, 程姣姣, 王虎生, 阮祥燕, 贾婵维. 达英-35对多囊卵巢综合征患者代谢与性激素的影响[J]. 首都医科大学学报, 2019, 40(4): 560-565.
[12]	闵敏, 阮祥燕, 赵越, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, 张露平, 王月姣, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型PCOS患者雄激素及糖脂代谢的影响[J]. 首都医科大学学报, 2019, 40(4): 572-577.
[13]	杜娟, 阮祥燕, Alfred O. Mueck. 口服避孕药对多囊卵巢综合征患者性功能的影响[J]. 首都医科大学学报, 2018, 39(4): 499-504.
[14]	金婧, 阮祥燕, 华琳, 李杨璐, 王利娟, 王虎生, 赵越, Alfred O. Mueck. 多囊卵巢综合征卵巢储备功能降低患者肥胖及糖脂代谢特征[J]. 首都医科大学学报, 2018, 39(4): 505-511.
[15]	王虎生, 阮祥燕, 李扬璐, 程姣姣, 谷牧青, 杜娟, 金凤羽, Alfred O. Mueck. 丙二醛、视黄醇与多囊卵巢综合征发病机制关系的探索[J]. 首都医科大学学报, 2018, 39(4): 512-516.